Open Label SKY-0515 Huntington's Disease Trial Phase 2
Summary
NIH ClinicalTrials.gov registered a Phase 2 open-label extension study (NCT07537075) for SKY-0515, an oral medication being evaluated for Huntington's Disease. The trial will enroll adults aged 25 and older with genetically confirmed HD to assess whether SKY-0515 can lower harmful proteins associated with the disease and improve symptoms. The study is registered as Phase 2 with an anticipated start date.
What changed
NIH ClinicalTrials.gov added a new registry entry for a Phase 2 clinical trial evaluating SKY-0515 as an oral treatment for Huntington's Disease. The study will include men and women aged 25 and older with genetically confirmed HD who meet physical and independence requirements.
Affected parties including clinical investigators, pharmaceutical companies, and patients interested in Huntington's Disease research can reference this registry entry for enrollment information and study design details. The trial is registered under identifier NCT07537075 and represents ongoing clinical development activity in the neurodegenerative disease space.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
An Open Label Extension of SKY-0515 in Participants With Huntington's Disease
Phase 2 NCT07537075 Kind: PHASE2 Apr 17, 2026
Abstract
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Conditions: Huntington's Disease (HD)
Interventions: SKY-0515
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.